The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While https://heidiokrl667541.fare-blog.com/39396034/glp-3-retatrutide-a-comparative-analysis